151 related articles for article (PubMed ID: 9445934)
1. [Reduction of cholesterol and myocardial infarction. Big differences between different groups when it comes to the therapeutic effect].
Håkansson J
Lakartidningen; 1997 Dec; 94(49):4619, 4622-3. PubMed ID: 9445934
[No Abstract] [Full Text] [Related]
2. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
Motz W
MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
[No Abstract] [Full Text] [Related]
3. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G
Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
[TBL] [Abstract][Full Text] [Related]
5. Meet the cholesterol busters.
Healy B
US News World Rep; 2004 Mar 22-29; 136(10):54. PubMed ID: 15069903
[No Abstract] [Full Text] [Related]
6. Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Prescrire Int; 1999 Aug; 8(42):116-20. PubMed ID: 11503831
[TBL] [Abstract][Full Text] [Related]
7. [Preventing infarct by lowering LDL. Is 100 the upper limit for every diabetic patient?].
MMW Fortschr Med; 2003 Sep; 145(38):60. PubMed ID: 14603687
[No Abstract] [Full Text] [Related]
8. [Consequences of the "A to Z" studies: Cholesterol in acute coronary syndrome early and aggressive reduction?].
März W
Herz; 2005 Feb; 30(1):78-80. PubMed ID: 16167397
[No Abstract] [Full Text] [Related]
9. ["No infarct without elevated LDL cholesterol"!].
Greten H
MMW Fortschr Med; 2008 Nov; 150(48):119. PubMed ID: 19125517
[No Abstract] [Full Text] [Related]
10. [Summary of the 'Cholesterol' guideline (first revision) of the Dutch College of Family Practice].
Bonneux L
Ned Tijdschr Geneeskd; 2000 Apr; 144(18):862-3. PubMed ID: 10816777
[No Abstract] [Full Text] [Related]
11. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.
Bruckert E; Giral P; Tellier P
Circulation; 2003 Jul; 107(25):3124-8. PubMed ID: 12835406
[No Abstract] [Full Text] [Related]
12. Updated guidelines support even lower cholesterol levels for at-risk patients.
Levenson D
Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
[No Abstract] [Full Text] [Related]
13. [Cholesterol lowering--Quo vadis? WOS (West of Scotland)--study of pravastin--a milestone in the prevention of myocardial infarct?!].
Fortschr Med Suppl; 1995; 170():1-7. PubMed ID: 9022407
[No Abstract] [Full Text] [Related]
14. Management of high blood cholesterol.
Smith MD; McGhan WF
Bus Health; 1996 Apr; 14(4):67-8, 70, 72-4. PubMed ID: 10157682
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of statin medications.
Kaplan RM; Golomb BA
Am Psychol; 2001 Apr; 56(4):366-7. PubMed ID: 11330239
[No Abstract] [Full Text] [Related]
16. [How I treat and manage cholesterol after myocardial infarction].
Capron L
Journ Annu Diabetol Hotel Dieu; 1996; ():199-209. PubMed ID: 8965423
[No Abstract] [Full Text] [Related]
17. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
[TBL] [Abstract][Full Text] [Related]
18. [Hypercholesterolemia in high risk patients. Targeting low goal values].
MMW Fortschr Med; 2001 Apr; 143(15):50-1. PubMed ID: 11349323
[No Abstract] [Full Text] [Related]
19. [Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions].
Szucs TD; Lüscher TF; Gutzwiller F
Schweiz Med Wochenschr; 1997 Nov; 127(44):1819-23. PubMed ID: 9446200
[TBL] [Abstract][Full Text] [Related]
20. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
MacNeil P
Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
